US FDA grants priority review to Bayer HealthCare's riociguat
This article was originally published in Scrip
Executive Summary
The US FDA has granted a priority review to Bayer HealthCare's new drug application (NDA) for riociguat for persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable diseases – for which it would be the first drug in the US for that condition – and pulmonary arterial hypertension (PAH).